Current issues and available options in combined hormonal contraception

被引:55
作者
Bitzer, Johannes [1 ]
Simon, James A. [2 ]
机构
[1] Univ Spital Basel, Frauenklin, Dept Obstet & Gynaecol, CH-4031 Basel, Switzerland
[2] George Washington Univ, Dept Obstet & Gynecol, Washington, DC 20036 USA
关键词
Hormonal contraceptives; Vaginal ring; Oral contraception; Transdermal patch; DOSE ORAL-CONTRACEPTIVES; BONE-MINERAL DENSITY; 30; MU-G; DEPOT-MEDROXYPROGESTERONE ACETATE; NONFATAL VENOUS THROMBOEMBOLISM; ESTROGEN-REPLACEMENT THERAPY; VAGINAL RING; ETHINYL ESTRADIOL; CYCLE CONTROL; TRANSDERMAL PATCH;
D O I
10.1016/j.contraception.2011.02.013
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
Development of hormonal contraception marked a revolutionary step in social change that has improved the lives of women and families worldwide. Since the first oral contraceptive was introduced in the 1960s, hormonal contraception has undergone various stages of advancement. Today, oral contraceptive regimens are safer and more tolerable, with equal or improved efficacy, than the early formulations. Incremental decreases in the dose of estrogens have helped to alleviate some of the unwanted estrogenic side effects of combined hormonal contraceptives. Progestogens have also evolved over time, and newer generations of progestins have minimal side effects. New delivery methods have further extended the range of options available to women. Among these, the transdermal patch and vaginal ring are widely used. This review examines available combined hormonal contraceptive options and compares them, where data are available, for efficacy, safety, cycle control, adverse events profiles and associated risks, and user preference and satisfaction. We also examine particular areas of interest, including bone mineral density, venous thrombosis and use of antiepileptic drugs. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:342 / 356
页数:15
相关论文
共 139 条
[1]
Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg of ethinyl estradiol and 3 mg of drospirenone [J].
Ahrendt, Hans-Joachim ;
Nisand, Israel ;
Bastianelli, Carlo ;
Gomez, Maria Angeles ;
Gemzell-Danielsson, Kristina ;
Urdl, Wolfgang ;
Karskov, Birgit ;
Oeyen, Luc ;
Bitzer, Johannes ;
Page, Geert ;
Milsom, Ian .
CONTRACEPTION, 2006, 74 (06) :451-457
[2]
Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel [J].
Ahrendt, Hans-Joachim ;
Makalova, Dagmar ;
Parke, Susanne ;
Mellinger, Uwe ;
Mansour, Diana .
CONTRACEPTION, 2009, 80 (05) :436-444
[3]
Long-term safety of an extended-cycle oral contraceptive (Seasonate): A 2-year multicenter open-label extension trial [J].
Anderson, F. D. ;
Gibbons, William ;
Portman, David .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2006, 195 (01) :92-96
[4]
Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol [J].
Anderson, FD ;
Gibbons, W ;
Portman, D .
CONTRACEPTION, 2006, 73 (03) :229-234
[5]
A multicenter, randomized study of an extended cycle oral contraceptive [J].
Anderson, FD ;
Hait, H .
CONTRACEPTION, 2003, 68 (02) :89-96
[6]
[Anonymous], 1995, J Clin Epidemiol, V48, P1513
[7]
[Anonymous], 1987, NEW ENGL J MED, V316, P650
[8]
The pharmacokinetics and efficacy of different estrogens are not equivalent [J].
Ansbacher, R .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2001, 184 (03) :255-263
[9]
Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results [J].
Archer, David F. ;
Jensen, Jeffrey T. ;
Johnson, Julia V. ;
Borisute, Hannah ;
Grubb, Gary S. ;
Constantine, Ginger D. .
CONTRACEPTION, 2006, 74 (06) :439-445
[10]
Combined oral contraceptive pills for treatment of acne [J].
Arowojolu, Ayodele O. ;
Gallo, Maria F. ;
Lopez, Laureen M. ;
Grimes, David A. ;
Garner, Sarah E. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (03)